Ben-Gurion University

Sorrento, BGN Technologies collaborate on Hepatitis C

Wednesday, July 17, 2013

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, and BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, have entered into an option and license agreement covering several anti-Hepatitis C Virus (HCV) antibody clones identified from patients who have recovered from HCV infections. Sorrento plans to develop these early findings into a potential therapeutic product.

[Read More]